Synopsis
Synopsis
0
JDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-n-ethyl-3-((1-dimethyl-amino)ethyl)-n-methylphenylcarbamate
2. 713, Ena
3. 713, Sdz Ena
4. Ena 713
5. Ena 713, Sdz
6. Ena-713
7. Ena713
8. Exelon
9. Hydrogen Tartrate, Rivastigmine
10. Rivastigmine
11. Rivastigmine Hydrogen Tartrate
12. Rivastigminetartrate
13. Sdz Ena 713
14. Tartrate, Rivastigmine Hydrogen
1. 129101-54-8
2. Rivastigmine Hydrogen Tartrate
3. Ena 713
4. Sdz-ena 713
5. Rivastigmine Bitartrate
6. Rivastigmine (tartrate)
7. (s)-3-(1-(dimethylamino)ethyl)phenyl Ethyl(methyl)carbamate (2r,3r)-2,3-dihydroxysuccinate
8. Rivastigmine Hydrogentartrate
9. Rivastigmine Tartrate (exelon)
10. 9iy2357jpe
11. Chebi:64358
12. (2r,3r)-2,3-dihydroxybutanedioic Acid;[3-[(1s)-1-(dimethylamino)ethyl]phenyl] N-ethyl-n-methylcarbamate
13. Rivastigmine Actavis
14. (2r,3r)-2,3-dihydroxybutanedioic Acid 3-[(1s)-1-(dimethylamino)ethyl]phenyl N-ethyl-n-methylcarbamate
15. Carbamic Acid, N-ethyl-n-methyl-, 3-[(1s)-1-(dimethylamino)ethyl]phenyl Ester, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
16. Rivastigmine Tartrate Salt
17. Unii-9iy2357jpe
18. Rivastach
19. Exelon Mr
20. Exelon Tds
21. Nimvastid (tn)
22. Carbamic Acid, N-ethyl-n-methyl-, 3-((1s)-1-(dimethylamino)ethyl)phenyl Ester, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
23. Rivastigmine Tartrate;
24. Rivastigmine L-tartrate
25. Rivastigmine Tartrate [usp]
26. Rivastigmine Tartrate- Bio-x
27. Mls006011143
28. Chembl1201092
29. Hms3678f17
30. Hms3884h05
31. Rivastigmine For System Suitability
32. Act03355
33. Mfcd03700731
34. Rivastigmine Tartrate [vandf]
35. S2087
36. Akos022179413
37. Rivastigmine Tartrate [usp-rs]
38. Ac-3487
39. Ccg-213410
40. Cs-0947
41. T01r548
42. As-13921
43. Br164357
44. Carbamic Acid, Ethylmethyl-, 3-((1s)-1-(dimethylamino)ethyl)phenyl Ester, (2r,3r)-2,3-dihydroxybutanedioate (1:1)
45. Carbamic Acid, Ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl Ester, (s)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1)
46. Hy-11017
47. N-ethyl-n-methylcarbamic Acid 3-[(1s)-1-(dimethylamino)ethyl]phenyl Ester (2r,3r)-2,3-dihydroxybutanedioate
48. Smr004702920
49. Rivastigmine (as Hydrogen Tartrate)
50. Rivastigmine Hydrogen Tartrate [mi]
51. Rivastigmine Tartrate [orange Book]
52. Am20080949
53. R0093
54. Rivastigmine Tartrate [usp Monograph]
55. Sw199663-2
56. Rivastigmine Hydrogen Tartrate [mart.]
57. D02558
58. Rivastigmine Hydrogen Tartrate [who-dd]
59. Rivastigmine Hydrogen Tartrate [ema Epar]
60. Q-101313
61. Rivastigmine Hydrogen Tartrate [ep Monograph]
62. Q27133236
63. 3-[(s)-1-(dimethylamino)ethyl]phenyl N-ethyl-n-methylcarbamate L-tartrate
64. N-ethyl-n-methylcarbamic Acid 3-[(s)-1-(dimethylamino)ethyl]phenyl Ester L-tartrate
65. (1s)-1-(3-{[ethyl(methyl)carbamoyl]oxy}phenyl)-n,n-dimethylethanaminium (2r,3r)-3-carboxy-2,3-dihydroxypropanoate
66. 3-[(1s)-1-(dimethylamino)ethyl]phenyl Ethyl(methyl)carbamate (2r,3r)-2,3-dihydroxybutanedioate
Molecular Weight | 400.4 g/mol |
---|---|
Molecular Formula | C18H28N2O8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 8 |
Exact Mass | 400.18456586 g/mol |
Monoisotopic Mass | 400.18456586 g/mol |
Topological Polar Surface Area | 148 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 402 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Rivastigmine tartrate |
Drug Label | Rivastigmine tartrate is a reversible cholinesterase inhibitor and is known chemically as (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate. Rivastigmine tartrate is commonly referred to in the pharmacological... |
Active Ingredient | Rivastigmine tartrate |
Dosage Form | Capsule |
Route | oral; Oral |
Strength | eq 4.5mg base; eq 6mg base; eq 1.5mg base; eq 3mg base |
Market Status | Tentative Approval; Prescription |
Company | Apotex; Alembic Pharms; Sun Pharm Inds; Watson Labs; Macleods Pharms; Dr Reddys Labs; Orchid Hlthcare |
2 of 2 | |
---|---|
Drug Name | Rivastigmine tartrate |
Drug Label | Rivastigmine tartrate is a reversible cholinesterase inhibitor and is known chemically as (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate. Rivastigmine tartrate is commonly referred to in the pharmacological... |
Active Ingredient | Rivastigmine tartrate |
Dosage Form | Capsule |
Route | oral; Oral |
Strength | eq 4.5mg base; eq 6mg base; eq 1.5mg base; eq 3mg base |
Market Status | Tentative Approval; Prescription |
Company | Apotex; Alembic Pharms; Sun Pharm Inds; Watson Labs; Macleods Pharms; Dr Reddys Labs; Orchid Hlthcare |
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
N06DA03
NDC Package Code : 65862-612
Start Marketing Date : 2023-12-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53104-7571
Start Marketing Date : 2016-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49706-1826
Start Marketing Date : 2010-01-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65372-1152
Start Marketing Date : 2011-01-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50379-0012
Start Marketing Date : 2014-03-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Through the acquisition, Almirall get exclusive rights to commercialize the Prometax (rivastigmine hydrogen tartrate), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Brand Name: Prometax
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Almirall
Deal Size: $64.2 million Upfront Cash: $48.1 million
Deal Type: Acquisition September 04, 2023
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Almirall
Deal Size : $64.2 million
Deal Type : Acquisition
Almirall Acquires Rights for an Alzheimer’s Product in Spain
Details : Through the acquisition, Almirall get exclusive rights to commercialize the Prometax (rivastigmine hydrogen tartrate), a multi-day transdermal patch for the treatment of Alzheimer’s disease.
Brand Name : Prometax
Molecule Type : Small molecule
Upfront Cash : $48.1 million
September 04, 2023
Details:
Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Brand Name: Exelon
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Brand Name : Exelon
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2022
Details:
Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Brand Name: Exelon
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia
Details : Exelon (rivastigmine tartrate) is an oral acetylcholinesterase inhibitor, which is approved for the treatment of mild to moderately severe dementia in people with Alzheimer's disease and Parkinson's disease..
Brand Name : Exelon
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Details:
Knight Therapeutics has acquired exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Brand Name: Exelon
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Knight Therapeutics
Deal Size: $180.0 million Upfront Cash: $168.0 million
Deal Type: Acquisition May 26, 2021
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Knight Therapeutics
Deal Size : $180.0 million
Deal Type : Acquisition
Details : Knight Therapeutics has acquired exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon trademark,...
Brand Name : Exelon
Molecule Type : Small molecule
Upfront Cash : $168.0 million
May 26, 2021
Details:
Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's disease.
Lead Product(s): Rivastigmine Tartrate
Therapeutic Area: Neurology Brand Name: Exelon
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Knight Therapeutics
Deal Size: $180.0 million Upfront Cash: $168.0 million
Deal Type: Acquisition April 23, 2021
Lead Product(s) : Rivastigmine Tartrate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Knight Therapeutics
Deal Size : $180.0 million
Deal Type : Acquisition
Knight Therapeutics to Acquire Regional Rights to Exelon®
Details : Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alz...
Brand Name : Exelon
Molecule Type : Small molecule
Upfront Cash : $168.0 million
April 23, 2021
N-Ethyl-N-Methyl Carbamoyl Chloride
CAS Number : 42252-34-6
End Use API : Rivastigmine Tartrate
About The Company : Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technologi...
(S)-3-1(- Dimethylamino)ethylphenol
CAS Number : 139306-10-8
End Use API : Rivastigmine Tartrate
About The Company : Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technologi...
3-(1-(dimethylamino)ethyl)phenol
CAS Number : 105601-04-5
End Use API : Rivastigmine Tartrate
About The Company : Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technologi...
3-(1-(dimethylamino)ethyl)phenol
CAS Number : 105601-04-5
End Use API : Rivastigmine Tartrate
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
(S)-3 -(1-(dimethylamino)ethyl)phenol
CAS Number : 139306-10-8
End Use API : Rivastigmine Tartrate
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
ethyl(methyl)carbamic chloride
CAS Number : 42252-34-6
End Use API : Rivastigmine Tartrate
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
?-(meta hydroxy phenyl) ethyldimethyl amine
CAS Number : 105601-04-5
End Use API : Rivastigmine Tartrate
About The Company : Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and Manufacturing APIs and Advanced Intermediates for Activ...
CAS Number : 63720-38-7
End Use API : Rivastigmine Tartrate
About The Company : Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and Manufacturing APIs and Advanced Intermediates for Activ...
(S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N- me...
CAS Number : 123441-03-2
End Use API : Rivastigmine Tartrate
About The Company : Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and Manufacturing APIs and Advanced Intermediates for Activ...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?